IP Library › Patent Application 12434346
Patent Application
App. No. 12/434,346

TREATING EYE DISORDERS USING INTESTINAL TREFOIL PROTEINS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/434,346
Abstract

Intestinal trefoil factors and nucleic acids encoding intestinal trefoil factors are disclosed. The intestinal trefoil factors disclosed are resistant to destruction in the digestive tract and can be used for the treatment of peptic ulcer diseases, inflammatory bowel diseases, eye disorders and other insults.

Claims (7)

1 . A method for enhancing corneal epithelial wound healing in a patient, said method comprising administering to the eye of said patient a polypeptide selected from the group consisting of human ITF (intestinal trefoil factor) and biologically active fragments thereof, wherein said biologically active fragments are wound healing fragments, and wherein said polypeptide is administered in an amount sufficient to enhance corneal epithelial wound healing.

2 . The method of claim 1 , wherein said polypeptide is human ITF.

3 . The method of claim 1 , wherein said corneal wound is caused by a bacterial infection.

4 . The method of claim 1 , wherein said polypeptide is administered in a dimeric form.

5 . A method for treating keratoconjunctivitis sicca (dry eyes) in a patient, said method comprising administering to the eye of said patient a polypeptide selected from the group consisting of the intestinal trefoil factor (ITF) set forth in SEQ ID NO.: 2 or SEQ ID NO.: 4 and biologically active fragments thereof, wherein said biologically active fragments are wound healing fragments.

6 . The method of claim 5 , wherein said polypeptide is the ITF set forth in SEQ ID NO.: 4 or a biologically active fragment thereof.

7 . The method of claim 5 , wherein said polypeptide is administered in a dimeric form.